International guidelines recommend KRAS mutation testing prior to prescribing anti-EGFR the monoclonal antibodies cetuximab and panitumumab for patients with advanced CRC and state that alternative therapy should be prescribed when mutations are detected [20]. The gene discussed is KRAS; the disease is colorectal carcinoma.